Children's Hospital Of Eastern Ontario

MASTER FORMULA SHEET – NON-STERILE MANUFACTURING

PRODUCT: **AZATHIOPRINE** 50 mg/mL SUSPENSION

Date Prepared: _____ **FINAL PRODUCT CHECKED BY:** _____

EXPIRY DATE: _____

INGREDIENT	MANUFACTURER	LOT #	MAN. EXPIRY DATE	FORMULA QUANTITY	QUANTITY USED	MFG BY	CHK BY
Azathioprine 50 mg tablet				20			
Ora-Blend®	Paddock			qs to 20 mL			

EQUIPMENT

- Mortar and Pestle
- Graduated Cylinder

MANUFACTURING DIRECTIONS

1. Crush tablets to make a fine powder in a mortar.
2. Levigate powder with a small amount of the vehicle to make a fine paste.
3. Continue to add vehicle until product liquid enough to transfer to a graduated cylinder.
4. Rinse mortar several times with vehicle and add to product in graduated cylinder.
5. QS to final volume with vehicle.
6. Dispense in amber plastic bottles. May be refrigerated or stored at room temperature.

FINAL APPEARANCE

Fine suspension of yellow particles.

SAMPLE LABEL

AZATHIOPRINE 50 mg/mL Suspension
Shake well. Room Temperature or Refrigerate.
Date Prepared: Date Expired:

STABILITY

60 days in fridge or at room temperature.

REFERENCE(S)

- Nahata MC, Hipple TF, Pediatric Drug Formulations, 4th ed. 2000, pp 17
- Allen LV, Erickson MA, Secundum Artem, Stability of Extemporaneously Prepared Pediatric Formulations using Ora-Plus ® with Ora-Sweet ® and Ora-Sweet SF ®, Part 1, Volume 5, Number 4, Paddock Laboratories Inc. May 1997
- Jew RK, Mullen RJ, Soo-Hoo W, Extemporaneous Formulations, The Children's Hospital of Philadelphia, American Society of Health System Pharmacist 2003, pp 6

Master Sheet Revision Dates: ***4 Feb 98; 7 July 03; 14 Oct 05; 16 Feb 06; 5 Oct 06*** ***Final Approval By:*** *KS/DI/CMB*